MedTrace Logo

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

NCT01970254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2206

Last updated 2022-08-15

No results posted yet for this study

Summary

This trial studies hepatitis B screening strategies of new cancer patients scheduled to undergo chemotherapy. Patients with cancer and hepatitis B virus infection are at risk of reactivation of infection after chemotherapy. Hepatitis B virus infection reactivation can be prevented by starting antivirals before chemotherapy in patients who are hepatitis B virus infection positive. Hepatitis B screening may help doctors prevent the reactivation of hepatitis B virus infection after chemotherapy.

Conditions

Interventions

OTHER

Hepatitis B Screening

Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jessica P Hwang · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-24
Primary Completion
2022-07-19
Completion
2022-07-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01970254 on ClinicalTrials.gov